Announcements Trials
Browse Landscape

Phase

Phase 1 119Phase 2 68Phase 1/2 62Phase 3 59Phase NA 17Phase 2/3 8Phase EARLY_PHASE1 2Phase 4 2

Status

Withdrawn 2

Sponsor Class

OTHER 24INDUSTRY 2OTHER_GOV 1

Study Type

Interventional 2

Sponsor

Cancer Type

Genitourinary 2

Conditions

Neoplasms 66Breast Neoplasms 64Prostatic Neoplasms 46Carcinoma, Non-Small-Cell Lung 40Neoplasm Metastasis 23Colorectal Neoplasms 21Multiple Myeloma 20Pain 19Leukemia, Myelogenous, Chronic, BCR-ABL Positive 16Anemia 16Keratosis, Actinic 15Lung Neoplasms 14Cancer Pain 14Lymphoma, Non-Hodgkin 12Lymphoma, Follicular 11Leukemia 11Leukemia, Lymphocytic, Chronic, B-Cell 10Carcinoma, Renal Cell 10Carcinoma, Hepatocellular 9Carcinoma 9Neuroendocrine Tumors 8Melanoma 8Lymphoma 8Ovarian Neoplasms 7Leukemia, Myeloid, Acute 7Uterine Cervical Neoplasms 6Recurrence 6Gastrointestinal Stromal Tumors 6Stomatitis 5Stomach Neoplasms 5

Interventions

5-aminolevulinic acid hexyl ester 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 4 × INDUSTRY × Urinary Bladder Neoplasms × Clear all
NCT06390111 2024-11-22

ABLE-42

Ferring Pharmaceuticals

Phase 4 Withdrawn
Genitourinary

Urinary Bladder Neoplasms

NCT00785694 2015-04-24

Recurrence of Bladder Cancer After Transurethral Resection With Hexvix

GE Healthcare

Phase 4 Withdrawn
Genitourinary

Urinary Bladder Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡